Alzheimer's Concept Sector Rises 2.33% on September 14, 2026
On September 14, 2026, the Alzheimer's concept sector closed up 2.33%, ranking 10th among concept sectors, with 42 stocks advancing. Sanli Pharmaceutical hit the daily limit, while ST Wanbang, Hotgen Biotech and Dongya Pharmaceutical gained 8.69%, 6.59% and 6.07%. The sector drew RMB 192 million in net main-force inflows, with Sanli Pharmaceutical leading at RMB 61.89 million.
At the close on September 14, 2026, the Alzheimer's concept sector rose 2.33%, ranking 10th among concept sectors by gain. Within the sector, 42 stocks advanced. Sanli Pharmaceutical hit the daily limit, while ST Wanbang, Hotgen Biotech and Dongya Pharmaceutical led the gainers, up 8.69%, 6.59% and 6.07% respectively. Chitianhua, Tonghua Golden-Horse and United Imaging Healthcare led the decliners, falling 2.83%, 2.62% and 0.74% respectively.
On the capital side, the Alzheimer's concept sector recorded a net main-force inflow of RMB 192 million for the day. Twenty-six stocks in the sector saw net main-force inflows, of which 11 exceeded RMB 10 million. Sanli Pharmaceutical led the sector with a net main-force inflow of RMB 61.8889 million; Dian Diagnostics, CONBA and BGI Genomics followed with net inflows of RMB 37.7221 million, RMB 31.7376 million and RMB 17.9816 million respectively. In terms of inflow ratios, CONBA, Sanli Pharmaceutical and Dian Diagnostics recorded main-force net inflow ratios of 16.75%, 14.69% and 10.35% respectively.
Among concept sectors for the day, lab-grown diamond, CRO and MLCC concepts rose 4.42%, 3.40% and 3.14% respectively, while weight-loss drug, recombinant protein and EDR concepts rose 2.73%, 2.63% and 2.56% respectively. Military equipment restructuring, genetically modified organism and China State Shipbuilding Corporation-related concepts fell 3.17%, 2.30% and 2.12% respectively.